Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is a human laboratory-based, randomized, cross-over study in which buprenorphine will be
administered to healthy volunteers (n=22) in 3 separate inpatient 2-night visits, at least 1
week apart. At each visit, the participant will receive a single dose buprenorphine, either
0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the
IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO.
Participants will be given naltrexone to produce opioid blockade to eliminate the risk for
opioid dependence in individuals without OUD. Timed blood samples will be collected up to 24
hours.